Recce Ltd has released a press release.
Bonus Canadian R&D Rebate Received
Filed with ASX ·
6ix hasn’t read this filing yet.
Recce Pharmaceuticals Ltd. on 6ix
Earlier from Recce Pharmaceuticals
- Scientia Completes Cohort Dosing in Phase I/II UTI Trial
- Scientia Doses Ahead of Schedule in Phase I/II UTI Trial
- Clarification - 5x Higher Concentration in Urine & Plasma
- Phase I Clinical Trial Data Review Complete
- A$801,604 R&D Rebate Advance Received
Later from Recce Pharmaceuticals
- Australian Patent Granted for RECCE Anti-Infectives
- Positive Patients Update - Special Access Scheme
- Phase I/II Burn Wound Infection Trial Stage 1 Complete
- Patients Dosed in R327 Diabetic Foot Infection Trial
- Next Dose Cleared in Rapid Infusion Phase I/II UTI Trial
Follow Recce Pharmaceuticals into a list and get an email when it puts out news.
Follow Recce Pharmaceuticals